Longevity Health Holdings, Inc. Research and Development Expense
Longevity Health Holdings, Inc. (XAGE) reported Research and Development Expense of $73.35 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- Longevity Health Holdings, Inc. research and development expense for the quarter ending 2026-06-30 was $73.35K, a 67.91% decline year-over-year.
- Longevity Health Holdings, Inc. research and development expense for the quarter ending 2026-03-31 was $55.49K, a 71.82% decline year-over-year.
- Longevity Health Holdings, Inc. research and development expense for the quarter ending 2025-12-31 was $104.08K, a 44.94% decline year-over-year.
- Longevity Health Holdings, Inc. research and development expense for the quarter ending 2025-09-30 was $227.99K, a 31.29% decline year-over-year.
- Longevity Health Holdings, Inc. research and development expense for fiscal 2025 was $788.89K, a 25.17% decline from fiscal 2024.
- Longevity Health Holdings, Inc. research and development expense for fiscal 2024 was $1.05M, a 57.78% decline from fiscal 2023.
- Longevity Health Holdings, Inc. research and development expense for fiscal 2023 was $2.50M, a 13.71% increase from fiscal 2022.
- Longevity Health Holdings, Inc. research and development expense for fiscal 2022 was $2.20M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $73.35K 10-Q · filed 2026-08-14 | $128.84K 10-Q · filed 2026-08-14 | $232.92K derived: sum of 3 quarters · filed 2026-08-14 | $460.91K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2026-03-31 | $55.49K 10-Q · filed 2026-05-15 | $159.57K derived: sum of 2 quarters · filed 2026-05-15 | $387.56K derived: sum of 3 quarters · filed 2026-05-15 | $616.17K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-12-31 | $104.08K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $332.07K derived: sum of 2 quarters · filed 2026-03-31 | $560.68K derived: sum of 3 quarters · filed 2026-08-14 | $788.89K 10-K · filed 2026-03-31 | ||
| 2025-09-30 | $227.99K 10-Q · filed 2025-11-14 | $456.60K derived: sum of 2 quarters · filed 2026-08-14 | $684.81K 10-Q · filed 2025-11-14 | $842.53K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-06-30 | $228.61K 10-Q · filed 2026-08-14 | $425.52K 10-Q · filed 2026-08-14 | $614.54K derived: sum of 3 quarters · filed 2026-08-14 | $946.34K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-03-31 | $196.91K 10-Q · filed 2026-05-15 | $385.93K derived: sum of 2 quarters · filed 2026-05-15 | $717.74K derived: sum of 3 quarters · filed 2026-05-15 | $821.80K derived: sum of 4 quarters · filed 2026-05-15 | ||
| 2024-12-31 | $189.02K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $520.82K derived: sum of 2 quarters · filed 2026-03-31 | $624.89K derived: sum of 3 quarters · filed 2026-03-31 | $1.05M 10-K · filed 2026-03-31 | ||
| 2024-09-30 | $331.81K 10-Q · filed 2025-11-14 | $435.87K derived: sum of 2 quarters · filed 2025-11-14 | $865.29K 10-Q · filed 2025-11-14 | $207.63K derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-06-30 | $104.07K 10-Q · filed 2025-08-14 | $533.49K 10-Q · filed 2025-08-14 | -$124.18K derived: sum of 3 quarters · filed 2025-08-14 | $1.47M derived: sum of 4 quarters · filed 2025-08-14 | ||
| 2024-03-31 | $429.42K 10-Q · filed 2025-05-15 | -$228.24K derived: sum of 2 quarters · filed 2025-06-17 | $1.36M derived: sum of 3 quarters · filed 2025-06-17 | $2.19M derived: sum of 4 quarters · filed 2025-06-17 | ||
| 2023-12-31 | -$657.66K derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-06-17 | $933.24K derived: sum of 2 quarters · filed 2025-06-17 | $1.76M derived: sum of 3 quarters · filed 2025-06-17 | $2.50M 10-K/A · filed 2025-06-17 | ||
| 2023-09-30 | $1.59M 10-Q · filed 2024-11-14 | $1.67M 10-Q · filed 2023-11-15 | $2.41M derived: sum of 2 quarters · filed 2024-11-14 | $3.15M 10-Q · filed 2024-11-14 | $3.24M 10-Q · filed 2023-11-15 | $3.80M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $823.66K 10-Q · filed 2024-08-14 | $1.56M 10-Q · filed 2024-08-14 | $2.21M derived: sum of 3 quarters · filed 2024-08-14 | $2.78M derived: sum of 4 quarters · filed 2024-08-14 | ||
| 2023-03-31 | $740.33K 10-Q · filed 2024-05-15 | $1.38M derived: sum of 2 quarters · filed 2024-05-15 | $1.95M derived: sum of 3 quarters · filed 2024-05-15 | |||
| 2022-12-31 | $641.46K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $1.21M derived: sum of 2 quarters · filed 2024-04-01 | $2.20M 10-K · filed 2024-04-01 | |||
| 2022-09-30 | $570.93K 10-Q · filed 2023-11-15 | $1.55M 10-Q · filed 2023-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STEPAN CO (SCL) | United States | $1.451B | -477.05 |
| CHURCH & DWIGHT CO INC /DE/ (CHD) | United States | $22.622B | 30.81 |
| ECOLAB INC. (ECL) | United States | $77.183B | 36.58 |
| PROCTER & GAMBLE Co (PG) | United States | $338.763B | 21.26 |